Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Akston Biosciences Corporation maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action. This single action is handled by 1 distinct examiner, EMCH, GREGORY S, who is also the busiest examiner for the portfolio. This concentration of work indicates a focused prosecution effort at this stage of the company's patent development.
Prosecution activity is limited to 1 distinct art unit. EMCH, GREGORY S is responsible for the 1 busiest examiner pending office action. This data suggests a narrow scope of active examination for the company at the present time. The presence of only 1 pending office action across 1 distinct examiner and 1 distinct art unit reflects a specific point of contact within the USPTO for the company's current innovations. This focus allows for a direct interaction between the company and EMCH, GREGORY S.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| EMCH, GREGORY S | 1 | 48.0% | +43.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19633161 | FC FUSION PROTEIN THERAPEUTICS FOR COMPANION ANIMAL OBESITY AND METHODS OF USE | EMCH, GREGORY S | — |
| Art Unit | Apps |
|---|---|
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19633161 | FC FUSION PROTEIN THERAPEUTICS FOR COMPANION ANIMAL OBESITY AND METHODS OF USE | EMCH, GREGORY S | 1678 | §103DP | Non-Final OA | — | Pending | Mar 30, 2026 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAkston Biosciences Corporation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Gregory S Emch has the most, with 1 of Akston Biosciences Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.